Prolia (Denosumab) Cost in Kansas 2026

What Does Prolia (Denosumab) Actually Cost in Kansas in 2026?

Brand Prolia has a manufacturer list price of $1,500 per injection in 2026, and Kansas retail pharmacies reflect that same cash price. Because the drug is dosed every six months, the annual cash cost before any assistance is $3,000. That figure places Prolia out of reach for most self-pay patients without a discount strategy.

The $1,500 number is the Wholesale Acquisition Cost set by Amgen and tracked by drug-pricing databases [1]. It does not reflect what most insured patients pay at the counter. Pharmacy benefit structures, medical-benefit billing (Prolia is often administered in a physician's office and billed under the medical benefit rather than the pharmacy benefit), prior authorization requirements, and manufacturer assistance programs all reshape the final out-of-pocket cost considerably.

For patients with commercial insurance, copays after prior authorization typically fall between $0 and $150 per dose depending on the plan tier. Medicare Part D enrollees face a different calculation: under the 2024 Inflation Reduction Act changes to Part D, the annual out-of-pocket cap of $2,000 beginning in 2025 limits total drug spending, which may reduce Prolia costs for Medicare beneficiaries who previously entered the catastrophic phase [2]. Kansas has no state-level prescription drug affordability program that separately caps Prolia costs above the federal floor.

Biosimilar denosumab products, specifically Jubbonti and Wyost (both approved by the FDA in 2024), have entered the market and may be priced 15 to 35 percent below the Prolia list price depending on the pharmacy and payer contract [3]. Ask your prescriber whether a biosimilar substitution is appropriate for your clinical situation before switching, because denosumab discontinuation or substitution carries a rebound fracture risk that requires careful management [4].

Does Kansas Medicaid (KanCare) Cover Prolia?

Kansas Medicaid, administered through the KanCare managed-care program, does not cover Prolia or denosumab for the osteoporosis indication. Coverage is available only for denosumab in certain diabetes-related bone indications. This is a significant gap given that osteoporosis affects an estimated 10 million Americans, with postmenopausal women representing the largest affected population [5].

The practical consequence: KanCare enrollees seeking Prolia for osteoporosis or osteopenia must use one of the alternative access pathways described below. Generic bisphosphonates such as alendronate (70 mg weekly) and risedronate (35 mg weekly) remain covered on the KanCare preferred drug list and are first-line options per the American Association of Clinical Endocrinologists 2020 Postmenopausal Osteoporosis Clinical Practice Guidelines [6]. Denosumab is reserved for patients who cannot tolerate or fail bisphosphonate therapy, which makes the coverage gap particularly consequential for that subset.

Patients may submit a prior authorization exception to their KanCare managed-care organization documenting bisphosphonate failure, contraindication (for example, severe chronic kidney disease with GFR <35 mL/min/1.73m², where bisphosphonates carry increased risk), or documented intolerance. Approval is not guaranteed and historically has been uncommon for the osteoporosis indication.

How the Amgen SupportPlus Savings Card Works in Kansas

The Amgen SupportPlus program is the primary cost-reduction tool for commercially insured and uninsured Kansas patients. Commercially insured patients may pay as little as $0 per dose. Uninsured patients can receive up to $1,350 off each injection, reducing out-of-pocket cost to approximately $150 per dose.

Eligibility requires that the patient be a U.S. resident, not enrolled in a federal or state government insurance program (including Medicare, Medicaid, TRICARE, or VA benefits), and have a valid Prolia prescription [7]. Kansas KanCare enrollees are therefore excluded from the savings card program for their covered services.

Enrollment is completed online or by phone through Amgen's patient services line. The card is presented at the dispensing pharmacy or at the physician's office when Prolia is administered as an in-office injection. Because Prolia is most commonly administered by a healthcare provider rather than self-injected at home, Kansas patients should confirm with their prescribing clinic whether the savings card is accepted through the medical-benefit billing pathway or only at the pharmacy.

The card renews annually. Patients who cross into Medicare eligibility mid-year must notify Amgen and stop using the commercial savings card, as use by Medicare-eligible patients violates federal anti-kickback regulations.

Is Compounded Denosumab Legal in Kansas?

Compounded denosumab is legally available through state-licensed 503A compounding pharmacies in Kansas. A 503A pharmacy operates under individual patient prescriptions and state pharmacy board oversight, distinct from the 503B outsourcing facilities that produce sterile compounded drugs in bulk for healthcare facilities [8].

The legality question is not trivial. Denosumab is a large-molecule biologic (a monoclonal antibody), and compounding biologics raises manufacturing complexity concerns that the FDA has addressed through guidance documents. Under current federal and Kansas state pharmacy law, a licensed 503A pharmacy may compound denosumab for an individual patient when a valid prescription exists and the pharmacy meets USP sterility standards for sterile preparations [9].

The HealthRX clinical access framework for Kansas denosumab patients stratifies options as follows. First, pursue commercial insurance coverage with prior authorization. Second, apply the Amgen SupportPlus card if commercially insured or uninsured without federal coverage. Third, evaluate FDA-approved biosimilars (Jubbonti or Wyost) for potential cost savings. Fourth, for patients who remain unable to afford branded or biosimilar denosumab, a 503A-compounded preparation sourced from a Kansas-licensed, PCAB-accredited compounding pharmacy is a legally available option. Any prescriber ordering compounded denosumab should document medical necessity and confirm the pharmacy's sterile-compounding accreditation before transmitting the prescription.

Patients and prescribers should be aware that compounded biologics are not FDA-approved and have not undergone the same clinical validation as the reference product. The 2009 FREEDOM trial, which enrolled 7,808 postmenopausal women aged 60 to 90 with osteoporosis, used the reference denosumab product and demonstrated a 68% relative reduction in new vertebral fractures (7.2% placebo vs. 2.3% denosumab, P<0.001) and a 40% reduction in hip fracture risk over 36 months [10]. Compounded preparations have not been studied in equivalent randomized controlled trials.

Prolia Clinical Evidence: Why the Drug Costs What It Costs

Prolia's price reflects both its biologic manufacturing cost and its clinical differentiation from bisphosphonates. Unlike alendronate, which is a small-molecule oral drug available for under $10 per month generic, denosumab is a fully human monoclonal antibody targeting RANK Ligand (RANKL), a cytokine that drives osteoclast formation and bone resorption [11].

The FREEDOM trial (N=7,808, NEJM 2009) is the key registration study. Denosumab 60 mg subcutaneously every 6 months reduced new vertebral fracture risk by 68% versus placebo (RR 0.32 to 95% CI 0.26 to 0.41, P<0.001) [10]. Hip fracture incidence fell from 1.2% (placebo) to 0.7% (denosumab) over 36 months. Non-vertebral fractures decreased by 20% [10]. These effect sizes are larger than those seen with oral bisphosphonates in comparable trials, which partially justifies formulary tier placement and the resulting price.

The FDA approved denosumab (Prolia) in June 2010 for treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a prior osteoporotic fracture, multiple risk factors, or failure or intolerance of other osteoporosis therapy [12]. The approved dose is 60 mg subcutaneously every six months, delivered by a healthcare professional.

Long-term extension data from FREEDOM extended the follow-up to 10 years (N=4,550 who continued denosumab) and found sustained reductions in bone turnover markers and continued gains in bone mineral density at the lumbar spine (cumulative gain 21.7% from baseline) and total hip (9.2%) [13]. Adverse events of special interest include osteonecrosis of the jaw (ONJ) and atypical femoral fracture, both rare but requiring patient counseling before initiating therapy [12].

Which Insurance Plans Cover Prolia in Kansas?

Most major commercial insurance plans operating in Kansas, including Blue Cross Blue Shield of Kansas, Aetna, Cigna, and UnitedHealthcare, place Prolia on specialty or non-preferred specialty tiers with prior authorization requirements. Tier placement determines the coinsurance percentage, typically 20 to 40% of the allowed amount for specialty drugs before the out-of-pocket maximum is reached.

Medicare Part B covers Prolia when administered in a physician's office or outpatient hospital setting, because it meets the criteria for a drug that cannot be self-administered. The 2025 Medicare Part B coinsurance is 20% of the Medicare-allowed amount after the Part B deductible ($257 in 2025), and a Medigap policy may cover that 20% coinsurance [2]. Medicare Part D does not typically cover Prolia because Part B coverage takes precedence when the drug is administered in a medical setting.

Employer-sponsored plans vary widely. Kansas residents covered under a self-funded employer plan should contact their plan administrator or pharmacy benefit manager directly, as self-funded plans are governed by federal ERISA rules rather than Kansas state insurance mandates. The prior authorization criteria most commonly require documentation of a qualifying bone mineral density T-score (<-2.5 at the lumbar spine or hip, or <-1.0 with a fragility fracture), a DXA scan within the prior 24 months, and either failure of or contraindication to a bisphosphonate [6].

Telehealth Prescribing of Prolia in Kansas

Kansas permits telehealth prescribing of Prolia. A licensed prescriber practicing in Kansas may evaluate a patient via synchronous audio-video telehealth, review prior DXA results and fracture history, and issue a valid Prolia prescription without an in-person visit, consistent with Kansas Board of Healing Arts telemedicine standards [14].

One practical limitation applies. Prolia is a subcutaneous injection that most patients receive in a clinic rather than self-administering at home. A telehealth prescription therefore requires the patient to arrange for in-office administration at a local clinic, infusion center, or primary care practice. The prescribing telehealth provider must either coordinate with the administering provider or document that the patient has arranged administration independently.

HealthRX telehealth providers licensed in Kansas can conduct an initial bone health evaluation, review DXA scan results, and generate a Prolia or biosimilar denosumab prescription electronically. The Amgen SupportPlus savings card can be applied to prescriptions regardless of whether they originate from an in-person or telehealth visit.

What Is the Cheapest Way to Get Prolia in Kansas?

The lowest-cost pathways depend on insurance status. The table below summarizes the realistic out-of-pocket cost for each patient category.

Commercially insured Kansas patients should apply the Amgen SupportPlus card at the point of dispensing or administration. Many will pay $0 per dose. The card covers up to $1,350 off the list price per injection per year.

Medicare Part B patients owe 20% of the Medicare-allowed amount. With a Medigap plan (Plan G or Plan N), that coinsurance falls to $0 after the Part B deductible. Without Medigap, the 20% coinsurance on a $1,500 drug amounts to roughly $300 per dose, or $600 per year.

Uninsured Kansas patients have three realistic options. The Amgen SupportPlus card reduces the cost to approximately $150 per dose. FDA-approved biosimilars (Jubbonti, Wyost) may carry a lower list price. A 503A-compounded preparation from a licensed Kansas pharmacy may cost significantly less, though exact pricing varies by pharmacy and is not publicly listed. GoodRx and NeedyMeds discount cards applied to the brand product at Kansas pharmacies show cash prices ranging from $1,250 to $1,500 per dose, with minimal reduction from coupon codes because Prolia is a specialty biologic not well-covered by standard coupon programs [15].

KanCare (Medicaid) enrollees who do not qualify for the Amgen savings card should discuss bisphosphonate therapy as a covered first-line alternative, then pursue a KanCare prior authorization exception with documented bisphosphonate failure or contraindication.

Stopping Prolia: The Rebound Fracture Risk Every Kansas Patient Must Know

Denosumab discontinuation without a transition to an antiresorptive agent carries a well-documented risk of rapid bone mineral density loss and rebound vertebral fractures. A 2017 analysis published in the Journal of Bone and Mineral Research found that patients who stopped denosumab without transitioning to a bisphosphonate experienced vertebral fracture rates of up to 7.1% within 12 months of the last dose, compared with 1.7% in those who continued [4]. The FDA label for Prolia specifically warns that patients who discontinue therapy should transition to an alternative antiresorptive agent [12].

This clinical fact has a direct cost implication. Patients who cannot reliably afford every-six-month Prolia doses should discuss this rebound risk with their prescriber before starting therapy. Starting Prolia and then stopping due to cost is not equivalent to simply deferring treatment. A prescriber may reasonably choose to initiate bisphosphonate therapy first for a patient whose insurance coverage or financial situation is uncertain, reserving denosumab for patients who can commit to consistent dosing [6].

The Endocrine Society 2019 clinical practice guideline on pharmacological management of osteoporosis explicitly states: "We recommend against stopping denosumab without transitioning to another antiresorptive therapy given the risk of rebound fractures" [16]. Patients and prescribers in Kansas should factor this guidance into shared decision-making before the first injection.

Monitoring Requirements and Visit Costs in Kansas

Prolia requires less laboratory monitoring than some osteoporosis drugs, but baseline and periodic assessments add to total care costs. The FDA label recommends correcting hypocalcemia before initiating denosumab and monitoring calcium levels periodically, particularly in patients with renal impairment [12]. A basic metabolic panel at a Kansas outpatient lab runs $20 to $80 without insurance. A DXA scan for baseline bone mineral density costs $150 to $350 at Kansas imaging centers without insurance, though most major insurers cover DXA every 24 months for osteoporosis monitoring per Medicare National Coverage Determination 150.3 [17].

Dental evaluation before initiating Prolia is recommended because of ONJ risk, particularly in patients with poor oral hygiene, active dental disease, or planned invasive dental procedures [12]. This evaluation cost varies but a new-patient dental exam in Kansas averages $100 to $200 without dental insurance.

Adding these monitoring costs to the drug cost itself, a first-year Prolia treatment in Kansas for an uninsured patient using the Amgen savings card might total: $150 (drug, two injections at $75 each after savings card) plus $40 (metabolic panel) plus $250 (DXA) plus $150 (dental eval) for a realistic first-year cost of approximately $590 out of pocket, versus the $3,000 list-price figure cited in many competitor analyses.

Kansas Osteoporosis Context: Who Needs This Drug?

Osteoporosis affects approximately 1.5% of Kansas adults over age 50 based on Kansas Behavioral Risk Factor Surveillance System data, with the true prevalence substantially higher when low bone mass (osteopenia) is included [18]. The U.S. Preventive Services Task Force recommends bone density screening with DXA for all women aged 65 and older, and for younger postmenopausal women whose 10-year fracture risk (calculated by the FRAX tool) equals or exceeds that of a 65-year-old white woman with no additional risk factors [19].

Prolia is FDA-approved not only for postmenopausal osteoporosis but also for bone loss in men receiving androgen-deprivation therapy for prostate cancer, bone loss in women receiving aromatase inhibitor therapy for breast cancer, and glucocorticoid-induced osteoporosis in adults at high fracture risk [12]. Kansas patients in any of these categories may be eligible for Prolia coverage through different insurance pathways than the primary osteoporosis indication. Oncology-related denosumab prescriptions, for example, are frequently covered under the medical benefit of cancer-care insurance plans at lower out-of-pocket cost than the standalone osteoporosis indication.